Program
chiauranib
Also written as “Chiauranib”.
Its studies are mostly in Small Cell Lung Carcinoma · Ovarian Neoplasms · Lymphoma, Non-Hodgkin · Sarcoma · Triple Negative Breast Neoplasms, led by Chipscreen Biosciences.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chipscreen Biosciences | 154 open or running | phase 3since Mar 29, 2021 | Apr 22, 2014 | Feb 28, 2027phase 2 · NCT06492915 |
Also a collaborator on its studies: h-j-cro-international-inc.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Apr 22, 2014.
- Mar 1, 2017Phase 1 study in Lymphoma, Non-HodgkinNCT03074825 · 5 enrolled · China
- May 22, 2017Phase 2 study in Ovarian NeoplasmsNCT03166891 · 25 enrolled · China
- Jul 10, 2017Phase 1 study in Small Cell Lung CarcinomaNCT03216343 · 48 enrolled · China
- Aug 4, 2017Phase 2 study in Carcinoma, HepatocellularNCT03245190 · 27 enrolled · China
- May 30, 2019Phase 2 study in Lymphoma, Non-HodgkinNCT03974243 · 9 enrolled · China
- Mar 29, 2021Phase 3 study in Small Cell Lung CarcinomaNCT04830813 · 184 enrolled · China
- Jun 3, 2021Phase 3 study in Ovarian NeoplasmsNCT04921527 · 454 planned · China
- Jan 26, 2022Phase 2 study in Small Cell Lung CarcinomaNCT05271292 · 36 planned · United States
- Apr 14, 2022Phase 1 study in Healthy VolunteersNCT05346601 · 16 enrolled · China
- Apr 14, 2022Phase 2 study in Triple Negative Breast NeoplasmsNCT05336721 · 9 enrolled · China
- May 4, 2022No phase study in Small Cell Lung CarcinomaNCT05371899 · 6 enrolled · China
- Aug 9, 2022Phase 2 study in SarcomaNCT05497843 · 40 enrolled · China
- Jun 27, 2024Phase 2 study in Pancreatic Ductal AdenocarcinomaNCT06492915 · 42 enrolled · China
- Feb 25, 2026Phase 3 study in Metastatic Pancreatic Ductal AdenocarcinomaNCT07445295 · 558 planned · China
Ahead
- Feb 28, 2027Primary completion: phase 2 study in Pancreatic Ductal AdenocarcinomaNCT06492915
- Jun 30, 2028Primary completion: phase 3 study in Metastatic Pancreatic Ductal AdenocarcinomaNCT07445295
TargetBeta
“Serine/threonine-protein kinase Aurora-B inhibitor; Vascular endothelial growth factor receptor inhibitor”ChEMBL 37, by rule
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07445295Metastatic Pancreatic Ductal Adenocarcinoma · China | 3 | Not yet recruiting | Jun 30, 2028 | 558 |
| NCT06492915Pancreatic Ductal Adenocarcinoma · China | 2 | Active, not recruiting | Feb 28, 2027 | 42 |
| NCT05497843Sarcoma · China | 2 | Completed | Jan 3, 2025 | 40 |
| NCT05371899Small Cell Lung Carcinoma · China | – | Completed | Mar 18, 2024 | 6 |
| NCT05346601Healthy Volunteers · China | 1 | Completed | Jun 28, 2022 | 16 |
| NCT05336721Triple Negative Breast Neoplasms · China | 2 | Terminated | Oct 31, 2024 | 9 |
| NCT05271292Small Cell Lung Carcinoma · United States | 2 | Recruiting | Mar 2025 | 36 |
| NCT04921527Ovarian Neoplasms · China | 3 | Recruiting | Dec 31, 2024 | 454 |
| NCT04830813Small Cell Lung Carcinoma · China | 3 | Completed | Apr 1, 2024 | 184 |
| NCT03974243Lymphoma, Non-Hodgkin · China | 2 | Completed | Dec 31, 2021 | 9 |
| NCT03245190Carcinoma, Hepatocellular · China | 2 | Completed | Nov 1, 2019 | 27 |
| NCT03216343Small Cell Lung Carcinoma · China | 1 | Completed | Nov 4, 2022 | 48 |
| NCT03166891Ovarian Neoplasms · China | 2 | Completed | Mar 20, 2019 | 25 |
| NCT03074825Lymphoma, Non-Hodgkin · China | 1 | Terminated | Aug 15, 2017 | 5 |
| NCT02122809Solid Tumors · China | 1 | Completed | Apr 2016 | 18 |
How it is read
Names in the registry
- “Chiauranib”, 14 entries
- “chiauranib”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 4 studies
- Ovarian Neoplasms, 2 studies
- Lymphoma, Non-Hodgkin, 2 studies
- Sarcoma, 1 study
- Triple Negative Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.